RDY — Dr. Reddy's Laboratories Limited

Earnings Call Summary for Dr. Reddy's Laboratories (Q1 2027)

1. Key Financial Results and Metrics

• Revenue: INR 8,071 crores ($853 million), a decline of 5.6% year-over-year but a sequential growth of 7.4%.
• EBITDA Margin: 12.5%, down from previous year due to lower lenalidomide sales and a provision of INR 240 crores related to semaglutide API challenges. Adjusted EBITDA margin (excluding provisions) was 15.4%.
• Profit Before Tax: INR 553 crores ($58 million), representing a margin of 6.8%.
• Profit After Tax: INR 443 crores ($47 million), a margin of 5%.
• Diluted EPS: INR 5.32.
• Operating Working Capital: INR 14,353 crores ($1.52 billion), a slight decrease from the previous quarter.
• CapEx: INR 307 crores ($32 million) for the quarter.
• Cash Flow: Negative cash flow of INR 216 crores ($23 million) before acquisition-related payouts.

2. Strategic Updates and Business Highlights

• The underlying base business (excluding lenalidomide) showed healthy double-digit growth across key geographies, particularly in North America, driven by new product launches and favorable currency movements.
• New product launches included complex generics like bosutinib and nintedanib, as well as oral semaglutide in India.
• The company is focused on strengthening its core business while building future growth engines in peptides, biosimilars, consumer health, and innovation.
• Notable partnerships include collaborations for developing XACDURO and securing Thai FDA approval for zoliflodacin.
• The company celebrated 25 years on the NYSE and received recognition for governance and sustainability.

3. Forward Guidance and Outlook

• The company anticipates a strong second half of the fiscal year with the resumption of semaglutide supplies expected in November.
• EBITDA margins are projected to improve towards the 20% mark, even without semaglutide, with expectations of high teens margins in the near term.
• The company plans to continue launching new products, targeting around 27 launches for the year, with at least one significant launch expected in the next quarter.

4. Bad News, Challenges, or Points of Concern

• Revenue decline was primarily attributed to lower lenalidomide sales and the impact of semaglutide API-related challenges, which resulted in a significant provision.
• The gross profit margin decreased by 1,039 basis points year-over-year, impacted by the semaglutide provision and increased costs due to the Middle East conflict.
• There are ongoing concerns regarding the competitive landscape for semaglutide, with new entrants expected in the market by the time supplies resume.
• The company faces risks related to FDA inspections and potential delays in product approvals, particularly for abatacept.

5. Notable Q&A Insights

• Management confirmed that the EBITDA margin could reach around 18% in the near term, with a goal of maintaining a trajectory towards 20%.
• The U.S. business is expected to see double-digit growth excluding lenalidomide and semaglutide, despite recent quarterly declines.
• The company is actively engaged in business development opportunities and has a cash surplus of INR 3,057 crores ($323 million) for potential acquisitions.
• There were discussions about the impact of recent U.S. tariff announcements on generics, with management expressing a cautious but optimistic view on the situation.
• The company acknowledged challenges in R&D productivity, particularly in the U.S. generics space, and emphasized corrective measures taken to improve future performance.

This summary encapsulates the key points from Dr. Reddy's earnings call, highlighting both the current performance and future outlook while addressing challenges faced by the company.